推荐产品
等級
pharmaceutical primary standard
API 家族
mannitol
製造商/商標名
EDQM
mp
167-170 °C (lit.)
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
InChI 密鑰
FBPFZTCFMRRESA-KVTDHHQDSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
應用
本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途,用户请自行负责。本标准品不适用于人类或动物使用。
根据欧洲药典,用于配制下列给定溶液:
根据欧洲药典,用于配制下列给定溶液:
- 参考溶液 (b),根据各论 1531,使用液相色谱法(通则 2.2.29)检测异麦芽酮糖醇中的相关物质
- 参考溶液 (a),根据各论 0559,使用薄层色谱法(通则 2.2.27)和红外光谱法鉴别甘露醇,并使用液相色谱法(通则 2.2.29)测试和检测相关物质
- 参考溶液 (b),根据各论 0435,使用薄层色谱法(通则 2.2.27)鉴定山梨醇
- 参考溶液 (b),根据各论 1381,使用气相色谱法(通则 2.2.28)测试相关物质
生化/生理作用
一种糖醇类甜味剂。 用于甜味抑制研究。
包裝
本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录。
其他說明
可能适用相应的销售限制。
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
其他客户在看
Sorbitol
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 3865-3867 (2019)
Heikki O Koskela et al.
Chest, 124(6), 2171-2177 (2003-12-11)
To compare a new bronchial provocation test, the mannitol challenge, with cold air and histamine challenges to demonstrate airway hyperresponsiveness (AHR) in patients with difficult-to-diagnose asthma. A prospective study. Thirty-seven consecutive patients with recently diagnosed, steroid-naive, mild, or atypical asthma
Heikki O Koskela et al.
Chest, 125(6), 1985-1992 (2004-06-11)
To define whether coughing during mannitol challenge is a nonspecific side effect of this challenge or is associated with asthma. A prospective study. University hospital. Thirty-seven steroid-naive, asthmatic subjects and 10 healthy subjects. The participants completed a symptom questionnaire, recorded
Heikki O Koskela et al.
Chest, 124(4), 1341-1349 (2003-10-14)
To compare the sensitivity and validity of mannitol, histamine, and cold air challenges to demonstrate the effect of inhaled corticosteroids (ICS) in asthma. A prospective study. Seventeen patients with recently diagnosed, steroid-naive asthma who fulfilled the diagnostic criteria of Finnish
Diana Bilton et al.
Thorax, 69(12), 1073-1079 (2014-09-24)
Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门